has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778891, hs_child_table_id=0, hs_updated_at=1774960559659, hs_published_at=1787681149919, description=Kurt Preugschat has over 11 years of statistical experience from Phase I to Phase IV clinical trials. He is a lead statistician, providing statistical support and oversight for numerous clinical trials associated with new drug applications (NDA), supplemental new drug applications (sNDA), and medical devices. His expertise includes the development of study designs to meet complex clinical questions and the measurement of desired outcomes. In addition, Kurt has extensive experience generating statistical analyses and creating complex SAS programs and macros used by study team., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/kurt-preugschat.png',altText='kurt-preugschat',fileId=194097561372}, linkedin=https://www.linkedin.com/in/kurt-preugschat-97298923a, hs_name=, hs_path=, lastname=Preugschat, hs_initial_published_at=1775839468505, hs_created_at=1709645745122, hs_is_edited=false, hs_deleted_at=0, name=Kurt, position=Director, Biostatistics, job=, slug=kurt-preugschat, email=, hs_updated_by_user_id=65712240}, second={}, third={}})
Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM)
|
has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778891, hs_child_table_id=0, hs_updated_at=1774960559659, hs_published_at=1787681149919, description=Kurt Preugschat has over 11 years of statistical experience from Phase I to Phase IV clinical trials. He is a lead statistician, providing statistical support and oversight for numerous clinical trials associated with new drug applications (NDA), supplemental new drug applications (sNDA), and medical devices. His expertise includes the development of study designs to meet complex clinical questions and the measurement of desired outcomes. In addition, Kurt has extensive experience generating statistical analyses and creating complex SAS programs and macros used by study team., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/kurt-preugschat.png',altText='kurt-preugschat',fileId=194097561372}, linkedin=https://www.linkedin.com/in/kurt-preugschat-97298923a, hs_name=, hs_path=, lastname=Preugschat, hs_initial_published_at=1775839468505, hs_created_at=1709645745122, hs_is_edited=false, hs_deleted_at=0, name=Kurt, position=Director, Biostatistics, job=, slug=kurt-preugschat, email=, hs_updated_by_user_id=65712240}, second={}, third={}})
Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM)
|
has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778891, hs_child_table_id=0, hs_updated_at=1774960559659, hs_published_at=1787681149919, description=Kurt Preugschat has over 11 years of statistical experience from Phase I to Phase IV clinical trials. He is a lead statistician, providing statistical support and oversight for numerous clinical trials associated with new drug applications (NDA), supplemental new drug applications (sNDA), and medical devices. His expertise includes the development of study designs to meet complex clinical questions and the measurement of desired outcomes. In addition, Kurt has extensive experience generating statistical analyses and creating complex SAS programs and macros used by study team., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/kurt-preugschat.png',altText='kurt-preugschat',fileId=194097561372}, linkedin=https://www.linkedin.com/in/kurt-preugschat-97298923a, hs_name=, hs_path=, lastname=Preugschat, hs_initial_published_at=1775839468505, hs_created_at=1709645745122, hs_is_edited=false, hs_deleted_at=0, name=Kurt, position=Director, Biostatistics, job=, slug=kurt-preugschat, email=, hs_updated_by_user_id=65712240}, second={}, third={}})
Administering Event-Driven Clinical Trials: A Biostatistical Analysis
|
has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778891, hs_child_table_id=0, hs_updated_at=1774960559659, hs_published_at=1787681149919, description=Kurt Preugschat has over 11 years of statistical experience from Phase I to Phase IV clinical trials. He is a lead statistician, providing statistical support and oversight for numerous clinical trials associated with new drug applications (NDA), supplemental new drug applications (sNDA), and medical devices. His expertise includes the development of study designs to meet complex clinical questions and the measurement of desired outcomes. In addition, Kurt has extensive experience generating statistical analyses and creating complex SAS programs and macros used by study team., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/kurt-preugschat.png',altText='kurt-preugschat',fileId=194097561372}, linkedin=https://www.linkedin.com/in/kurt-preugschat-97298923a, hs_name=, hs_path=, lastname=Preugschat, hs_initial_published_at=1775839468505, hs_created_at=1709645745122, hs_is_edited=false, hs_deleted_at=0, name=Kurt, position=Director, Biostatistics, job=, slug=kurt-preugschat, email=, hs_updated_by_user_id=65712240}, second={}, third={}})
Inside a CRO: The Impact of a Biostatistician in Clinical Research
|
has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778868, hs_child_table_id=0, hs_updated_at=1715694281220, hs_published_at=1787681149919, description=Paul Pappas is a Senior Director of Biostatistics, bringing more than 20 years of experience to the team. His experience includes phase I-IV clinical trials as well as observational prospective cohort and registry studies. His therapeutic experience encompasses Autoimmune diseases, Cardiology, CNS, Infectious diseases, medical devices, Oncology, Rare diseases, and Vaccines. Paul has also co-authored over 30 manuscripts published in peer-reviewed medical journals., avatar=Image{width=626,height=710,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Paul-Pappas.png',altText='Paul-Pappas',fileId=167378452645}, linkedin=https://www.linkedin.com/in/paul-pappas-86176ab, hs_name=, hs_path=, lastname=Pappas, hs_initial_published_at=1775839468505, hs_created_at=1709645745099, hs_is_edited=false, hs_deleted_at=0, name=Paul, job=, slug=paul-pappas, email=, hs_updated_by_user_id=65712240}, second={}, third={}})
Best Practices for Biostatisticians: Preparing for Interim Analysis in Clinical Trials
|
has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778868, hs_child_table_id=0, hs_updated_at=1715694281220, hs_published_at=1787681149919, description=Paul Pappas is a Senior Director of Biostatistics, bringing more than 20 years of experience to the team. His experience includes phase I-IV clinical trials as well as observational prospective cohort and registry studies. His therapeutic experience encompasses Autoimmune diseases, Cardiology, CNS, Infectious diseases, medical devices, Oncology, Rare diseases, and Vaccines. Paul has also co-authored over 30 manuscripts published in peer-reviewed medical journals., avatar=Image{width=626,height=710,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Paul-Pappas.png',altText='Paul-Pappas',fileId=167378452645}, linkedin=https://www.linkedin.com/in/paul-pappas-86176ab, hs_name=, hs_path=, lastname=Pappas, hs_initial_published_at=1775839468505, hs_created_at=1709645745099, hs_is_edited=false, hs_deleted_at=0, name=Paul, job=, slug=paul-pappas, email=, hs_updated_by_user_id=65712240}, second={}, third={}})
Phase III Case Study: Adapting in the Face of Adversity
|
has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778845, hs_child_table_id=0, hs_updated_at=1754641622943, hs_published_at=1787681149919, description=Brian Beus is a Principal Biostatistician with more than 25 years experience supporting the statistical analysis of data through all phases of clinical trials across many therapeutic areas. He has extensive experience in leading teams and working with sponsors through study design, protocol development, adaptive design, statistical analysis plans, statistical analysis, clinical study reports, regulatory submissions, and regulatory responses., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/brian-beus.png',altText='brian-beus',fileId=194097831688}, linkedin=https://www.linkedin.com/in/brian-beus-66033333, hs_name=, hs_path=, lastname=Beus, hs_initial_published_at=1775839468505, hs_created_at=1709645745076, hs_is_edited=false, hs_deleted_at=0, name=Brian, job=, slug=brian-beus, email=, hs_updated_by_user_id=65712240}, second={}, third={}})
Pros and Cons: Innovative Study Designs vs. Traditional FIH
|
has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778854, hs_child_table_id=0, hs_updated_at=1715695005945, hs_published_at=1787681149919, description=Rosa Canals López has 15 years of experience in managing Phase I-IV clinical trials, including >7 years of Clinical Management experience. Her focus is on Phase I studies and CAR-T, with additional experience in oncology, hematology, pediatrics, infectious diseases, cardiology, and nephrology., avatar=Image{width=533,height=710,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Rosa-Canals.png',altText='Rosa-Canals',fileId=167374630834}, linkedin=https://www.linkedin.com/in/rosa-maria-canals-l%C3%B3pez-74902194, hs_name=, hs_path=, lastname=Canals López, hs_initial_published_at=1775839468505, hs_created_at=1709645745085, hs_is_edited=false, hs_deleted_at=0, name=Rosa, job=, slug=rosa-canals-lópez, email=, hs_updated_by_user_id=65712240}, second={}, third={}})
Overview: Innovative Study Designs vs. Traditional FIH
|
has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778854, hs_child_table_id=0, hs_updated_at=1715695005945, hs_published_at=1787681149919, description=Rosa Canals López has 15 years of experience in managing Phase I-IV clinical trials, including >7 years of Clinical Management experience. Her focus is on Phase I studies and CAR-T, with additional experience in oncology, hematology, pediatrics, infectious diseases, cardiology, and nephrology., avatar=Image{width=533,height=710,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Rosa-Canals.png',altText='Rosa-Canals',fileId=167374630834}, linkedin=https://www.linkedin.com/in/rosa-maria-canals-l%C3%B3pez-74902194, hs_name=, hs_path=, lastname=Canals López, hs_initial_published_at=1775839468505, hs_created_at=1709645745085, hs_is_edited=false, hs_deleted_at=0, name=Rosa, job=, slug=rosa-canals-lópez, email=, hs_updated_by_user_id=65712240}, second={}, third={}})
